Obatoclax, Saliphenylhalamide, and Gemcitabine Inhibit Influenza A Virus Infection*5

Received for publication, June 15, 2012, and in revised form, August 21, 2012 Published, JBC Papers in Press, August 21, 2012, DOI 10.1074/jbc.M112.392142

Oxana V. Denisova, Laura Kakko, Lin Feng, Jakob Stenman, Ashwin Nagaraj, Johanna Lampe, Bhagwan Yadav, Tero Aittokallio, Pasi Kaukinen, Tero Ahola, Suvi Kuivanen, Olli Vapalahti, Anu Kantele, Janne Tynell, Ilkka Julkunen, Hannimari Kallio-Kokko, Henrik Paavilainen, Veijo Huukkanen, Richard M. Elliott, Jef K. De Brabander, Xavier Saelens, and Denis E. Kainov5

From the Institute for Molecular Medicine Finland, FIMM, the Minerva Foundation Institute for Medical Research, the Institute of Biotechnology, the Haartman Institute, the Helsinki University Hospital Laboratory, the National Institute for Health and Welfare, and the Institute of Clinical Medicine, Helsinki FI-00290, Finland, the Department of Virology, University of Turku, Turku FI-20520, Finland, the Centre for Biomolecular Sciences, University of St. Andrews, Fife KY16 9ST, United Kingdom, the Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, and the Department for Molecular Biomedical Research, VIB and Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium

Influenza A viruses (IAVs) infect humans and cause significant morbidity and mortality. Different treatment options have been developed; however, these were insufficient during recent IAV outbreaks. Here, we conducted a targeted chemical screen in human nonmalignant cells to validate known and search for novel host-directed antivirals. The screen validated saliphenylhalamide (SaliPhe) and identified two novel anti-IAV agents, obatoclax and gemcitabine. Further experiments demonstrated that Mcl-1 (target of obatoclax) provides a novel host target for IAV treatment. Moreover, we showed that obatoclax and SaliPhe inhibited IAV uptake and gemcitabine suppressed viral RNA transcription and replication. These compounds possess broad spectrum antiviral activity, although their antiviral efficacies were virus-, cell type-, and species-specific. Altogether, our results suggest that phase II obatoclax, investigational SaliPhe, and FDA/EMEA-approved gemcitabine represent potent antiviral agents.

Influenza A viruses (IAVs)2 are enveloped viruses with segmented negative-sense single-stranded RNA genome. The rapid accumulation of mutations in IAV genomes enables the emerging viruses to evade the immunity developed after vaccination or previous infections with IAV and cause yearly epidemics and major pandemics with high morbidity and a great number of severe and fatal cases. Human IAVs invade the respiratory tract causing acute respiratory infections. Ocular involvement is also common. IAVs replicate in lung and retinal epithelial cells as well as in dendritic cells, type II pneumocytes, and alveolar macrophages (1–3). The replication cycle starts when the hemagglutinin (HA) proteins of the IAV virion recognize cell surface receptors. Then the IAV particle is taken up and transported via the endocytic pathway. Acidification of the endosome by cellular vacuolar ATPase (vATPase) and the virion interior by viral matrix protein 2 (M2) triggers HA-mediated fusion of viral and endosomal membranes, and the uncoating of viral nucleocapsid proteins (vRNPs) from the lipid envelope and matrix protein M1 shell. The vRNPs that contain PB1, PB2, and PA polymerase subunits, nucleoprotein (NP), and genomic viral RNAs (vRNAs) are imported to the nucleus, from which the viral genes direct the production of new viral components. These assemble into new virus particles at the plasma membrane which bud and release from the cell to infect other cells.

To ensure efficient production of infectious viral particles, IAV subverts endocytosis, transcription, translation, apoptosis, and other cellular functions (4). These functions could be perturbed by small molecules to inhibit IAV infection. Here, we evaluated a set of small molecules that affect cellular functions implicated in IAV infection to find novel and validate known IAV inhibitors, to provide novel insight into the biological process of IAV-host cell interaction, and to establish a foundation for the

* This work was supported, in whole or in part, by National Institutes of Health Grants CA90349 and CA95471. This work was also supported by the Jane and Aatos Erkko Foundation, Centre for International Mobility (CIMO), the Academy of Finland Grants 138644 and 225882, and Robert A. Welch Foundation Grant I-1422.

This article contains supplemental Table 1, Figs. S1 and S2, and additional references.

1 To whom correspondence should be addressed: Institute for Molecular Medicine Finland FIMM, Tukholmankatu 8, 00290, Helsinki, Finland. Tel.: 358-50-415-5460; E-mail: denis.kainov@helsinki.fi.

2 The abbreviations used are: IAV, influenza A virus; AM, Avicel medium; ATS, activity and toxicity score; CTG, Cell Titer Glo viability assay; hpi, hours postinfection; McI, myeloid leukemia cell; MDCK, Madin-Darby canine kidney; m.o.i., multiplicity of infection; NP, nucleoprotein; PBMC, peripheral blood mononuclear cell; RNP, ribonucleoprotein; RPE, retinal pigment epithelial; SaliPhe, saliphenylhalamide; TPCK, L-1-tosylamido-2-phenylethyl chloromethyl ketone; v, vacuolar; VGM, virus growth medium.
development of host-directed antivirals. These antivirals could overcome the problem of emerging resistance to available anti-influenza drugs that target viral neuraminidase and M2.

**Experimental Procedures**

**Compounds**—Supplemental Table 1 summarizes compounds used in this study and their suppliers. Saliphenylhalamide (Saliep) was synthesized by Jef De Brabander’s group as described in Ref. 5. 10 mM compounds in 100% dimethyl sulfoxide (Sigma-Aldrich) were stored at −80 °C until use.

**Cells and Viruses**—To obtain human macrophages, peripheral blood mononuclear cells (PBMCs) were isolated from theuffy coat preparations of voluntary blood donors (Finnish Red Cross) using lymphocyte separation medium (PAA) and cultured for 7 days in macrophage serum-free medium (Invitrogen) supplemented with 10 ng/ml human granulocyte macrophage-colony-stimulating factor (GM-CSF; Sigma-Aldrich) (6). PBMC-derived macrophages, human telomerase reverse transcriptase (hTERT)-immortalized retinal pigment epithelial (RPE), human adenocarcinomic alveolar basal epithelial (A549), Madin-Darby canine kidney (MDCK), monkey vero-E6 and B-Vero cells were infected with influenza A/PR-NS116-GFP (PR8-GFP), A/WSN/33 (WSN), A/PR/8/34 (PR8), A/Sydney/5/1997 (H3N2), B/Shandong/7/97 (InfB), human echovirus 6 (Echo6, GenBank accession: JQ929657), Sindbis (SINV, Ilomantsi-2002A strain), Semliki forest (SFV), Bunyamwera (BUNV), measles (MeV, Schwarz vaccine strain), herpes simplex 1 (HSV-1, KOS strain), vaccinia virus (VACV), or mock-infected as described in Refs. 7–14. The cells and viruses were propagated at 37 °C in 5% CO2.

**Targeted Screening of Chemical Compounds against Reporter IAV Strain**—The compound efficacy testing against PR8-GFP was performed in 384-well plates in RPE cells, which mimic the natural environment for IAV infection (15, 16). Approximately 2500 RPE cells/well were seeded using Multidrop 384 (Thermo) containing 1.2% Avicel (FMC Biopolymer), 0.2% BSA, 2 mM L-glutamine, 50 units/ml PenStrep, and 1 mM L-glutamine, 0.2% BSA, 50 units/ml PenStrep, 2 mM L-glutamine, and 1 mM L-glutamine, 0.2% BSA, 50 units/ml PenStrep, 2 mM L-glutamine, and 1 mM L-glutamine.

**Virus Titration**—Compound antiviral efficacies were further validated using plaque assays. Cells were treated with a compound at effective but noncytotoxic concentrations or remained nontreated and infected with dedicated virus at m.o.i. 0.1. Supernatants were collected 24–72 hpi. IAV-containing supernatants were diluted in DEMEM-based VGM containing 0.2% BSA, 50 units/ml PenStrep, 2 mM L-glutamine, and 1 μg/ml TPCK-trypsin in minimal essential medium (Invitrogen) and incubated for 2 days. The cells were fixed using 4% formaldehyde (Sigma-Aldrich) in PBS and stained with 0.1% crystal violet (Sigma-Aldrich) in 1% methanol (Sigma-Aldrich), 20% ethanol (Altia Oy), and 3.6% formaldehyde (Sigma-Aldrich). Plaque-forming units were calculated.

For other viruses the titration procedure slightly differed from the one described above. Echo6 virus was titered on A549 cells, and both VGM and AM contained 0.4 μg/ml TPCK-trypsin. SINV, SFV, HSV-1, and VACV were titered on Vero-E6.

Potent Influenza Antivirals
cells, and VGM was supplemented with 5% FBS, 2 mM l-glutamine, and 50 units/ml PenStrep in DMEM, and TPKC-trypsin was omitted. BUNV was titered on Vero-E6 cells, and supernatants were diluted in PBS containing 2% newborn calf serum (Invitrogen), AM contained 0.6% Avicel, and 2% newborn calf serum in minimal essential medium, and cells were incubated with AM for 3 days. Titers of HSV-1 were determined by infecting 12-well plates of B-Vero cells with serial dilutions of supernatants in DMEM containing 7% heat-inactivated fetal calf serum (FCS; Invitrogen) and 20 μg/ml human immunoglobulin G (Baxter). Cells were fixed with methanol for 3 min and stained with 0.1% crystal violet in 2% ethanol. The degree of inhibition mediated by a compound was calculated as a ratio between virus titers in nontreated and compound-treated cells.

**Immunofluorescence**—Compound-treated or nontreated RPE cells were infected with WSN IAV at m.o.i. 30 on ice for 1 h. Cells were washed twice with ice-cold VGM, overlaid with the media with or without compound, and incubated at 37 °C for 1–4 h. Cells were fixed with 4% paraformaldehyde (in PBS). PBS with 1% BSA and 0.1% Triton X-100 was used for blocking and permeabilization of the fixed cells and for dilution of antibodies. NP and M1 of WSN were stained with corresponding rabbit polyclonal antibodies (1:1000; from I. J. laboratory), and the secondary antibody was Alexa Fluor 488 goat anti-rabbit IgG (H+L) (1:1000, Invitrogen Molecular Probes). Mcl-1 was stained with anti-human MCL-1 (1:100; clone 22/Mcl-1; BD Transduction Laboratories). Secondary antibody was Alexa Fluor 594 goat anti-mouse IgG (1:2000; Invitrogen). Nuclei were counterstained with DAPI. Images were captured with Nikon 90i microscope and processed with NIS Elements AR software. Note, obatoclax produces autofluorescence (absorbance peak, 490 nm; emission peak, 550 nm (17)).

**Immunobots**—RPE cells were treated with 1 μM SaliPhe, 10 μM gemcitabine or 1 μM obatoclax or remained untreated and then infected with WSN IAV at m.o.i. 3. At 4, 8, or 12 hpi cells were washed twice with PBS, lysed with 2× SDS-sample buffer, and sonicated to dissolve aggregates. Proteins were resolved by electrophoresis in gradient 4–20% SDS-PAGE and transferred to polyvinylidene fluoride membrane (GE Healthcare). Membrane was blocked with 5% milk in Tris-buffered saline (TBS) and incubated with primary guinea pig anti-NS1 (1:2000), rabbit anti-M1 (1:2000), mouse anti-LRP130 (1:100, clone G-10; Santa Cruz Biotechnology), rabbit anti-NP (1:500; from I. J. laboratory), or mouse anti-β-actin (1:5000; Sigma-Aldrich) antibody for 1 h at room temperature. Membrane was washed three times for 10 min with TBS buffer containing 0.3% Tween 20 (Twee/TBS) and incubated for 1 h at room temperature with secondary antibodies conjugated to infrared dyes 680LT or 800CW (1:20,000, Li-Cor Biosciences). After three washes for 10 min with Tween/TBS buffer and one with TBS, membranes were scanned on an Odyssey scanner (Li-Cor Biosciences).

**Strand-specific Viral RNA Detection**—Reverse-transcription and strand-specific quantitative PCRs were performed as described in Ref. 18.

**Cytokine/Chemokine Profiling**—Compound-treated or nontreated RPE cells were infected with WSN at m.o.i. 3. The medium was replaced after 1 h of infection. At 24 hpi the supernatants were collected and assayed for interferon β and λ levels by ELISA (PBL Interferon source). In addition, the levels of 26 different chemokines/cytokines in the supernatants were assayed using human cytokine array panel A kit (R&D Systems).

**RESULTS**

**Eight Host-directed Compounds Inhibit Infection of Human Nonmalignant Cells with Reporter IAV Strain**—A total of 201 host-directed chemical compounds have been preselected for this study (supplemental Table S1). These include known IAV inhibitors, such as gemfibrozil and TOFA (lipid metabolism), 3-methyladenine and wortmannin (autophagy), 17-AAG and bortezomib (protein quality control), fluorouracil and cytarabine (de novo nucleotide biosynthesis). Notably, the antiviral efficacy of these compounds has been demonstrated mainly in cancer cell lines. Our drug set also contains functional analogs of known IAV inhibitors, such as erlotinib and gefitinib (analogs of PD153035), 17-DMAG (analogs of 17-AAG), carfilzomib (analog of bortezomib), leflunomide and gemcitabine (analog of fluorouracil), and a pool of potential IAV inhibitors that target the cell cycle, apoptotic pathways, and other functions that could be essential for IAV infection of a host cell.

We have tested the set of 201 compounds in nonmalignant human RPE cells at different concentrations against infection with reporter IAV strain (PR8-GFP). This strain expresses the NS1,116-GFP fusion which allows monitoring antiviral efficacy of the compounds by measuring GFP fluorescence and identification of small molecules that target stages of IAV infection ranging from IAV attachment to viral protein synthesis and quality control (9). Compound cytotoxicity testing was performed in parallel to calculate selectivity indexes (Fig. 1A). We identified five novel (obatoclax, gemcitabine, carfilzomib, NVP-AUY922, and 17-DMAG) and validated three known (SaliPhe, bortezomib, and 17-AAG (9, 19, 20)) IAV inhibitors that selectively suppressed IAV-mediated GFP expression at
noncytotoxic concentrations in dose-dependent manner in RPE cells (Fig. 1, B and C).

Three Host-directed Compounds Inhibit Infection of Human Nonmalignant Cells with Wild Type IAV Strains—The identified compounds have been demonstrated to target cellular vATPase, proteasome, heat shock protein 90 (HSP90), ribonucleotide reductase, or induced myeloid leukemia cell differentiation protein Mcl-1 (5, 17, 21, 22). Therefore, we next selected representative inhibitors for each of the 5 targets and tested them against two wild type IAV strains (PR8 and WSN) in human RPE cells and PBMC-derived macrophages. The effect of the drugs on cell survival and virus progeny production was examined. Potent inhibitors of Mcl-1, ribonucleotide reductase, and vATPase were found to exhibit dose-dependent antiviral activity which could be expressed in positive ATS. Inhibitors of proteasomes showed a moderate effect, and HSP90 inhibitors were ineffective at the selected concentrations, which could be expressed in neutral or negative ATS, respectively (Fig. 2, A and B). These results suggest that cellular Mcl-1, ribonucleotide reductase, and vATPase could represent essential host factors for wild type IAV infection. The proteasome could also be involved, but the therapeutic window was too narrow to allow a final conclusion. By contrast, HSP90 is not required by wild type, but is exploited by the mutant IAV strain containing an altered NS1, indicating that full-length NS1 could perform HSP90 function during IAV infection.

Virus-, Cell Type-, and Species-specific Antiviral Activity of Three Compounds—We next tested whether obatoclax, gemcitabine, and SaliPhe inhibit seasonal H3N2 IAV and InfB infections. Supplemental Fig. S1 shows that obatoclax and SaliPhe, by contrast to gemcitabine, rescued RPE cells from infections with these viruses. This result indicates that obatoclax and SaliPhe could possess anti-IAV and anti-InfB activity, whereas gemcitabine activity could be limited to certain influenza strains.
concentrations than those needed to mediate cancer cell death (supplemental Fig. S1). Interestingly, gemcitabine was unable to rescue IAV-infected A549 cells, suggesting that gemcitabine activity could be cell type-specific. We also tested whether obatoclax, gemcitabine, and SaliPhe possess species-specific antiviral activity and found that obatoclax, by contrast to gemcitabine and SaliPhe, was less effective in MDCK cells than in RPE or A549 (Fig. 2A and supplemental Fig. S1).

We next explored whether these compounds display antiviral activity against several other viruses of different families. Compound efficacy and cytotoxicity testing was performed against BUNV, MeV, SINV, SFV, Echo6, HSV-1, and VACV in dedicated cell lines (supplemental Fig. S2). Further, we titered the viruses produced by cells nontreated or treated with effective but noncytotoxic concentration of the compound. Table 1 shows the degrees of inhibition of virus production mediated by

FIGURE 2. Obatoclax, gemcitabine, and SaliPhe efficiently attenuate replication of wild type IAV strains in human RPE cells and PBMC-derived macrophages at noncytotoxic concentrations. A, the antiviral efficacy and cytotoxicity of five representative inhibitors of Bcl2-like proteins, ribonucleotide reductase, vATPase, proteasome, or HSP90 were examined in noninfected (blue curves) and PR8- or WSN-infected (green and red curves) RPE cells and macrophages using a CTG assay. The error bars represent the S.D. The ATS are shown. B, PR8 IAVs produced in nontreated or obatoclax- (0.4 μM), gemcitabine- (1 μM), or SaliPhe- (3 μM) treated human macrophages and RPE cells were titered on MDCK cells. Representative plaque assays and degrees of inhibition of PR8 virus production are shown.

TABLE 1

| Virus | Group | Family          | Cell line | Obatoclax | Gemcitabine |
|-------|-------|-----------------|-----------|-----------|-------------|
| BUNV  | (−) ssRNA | Bunyaviridae    | Vero      | >6 logs (1 μM) | >4 logs (3 μM) |
| MeV   | (+) ssRNA | Paramyxoviridae | Vero      | ND        | ND          |
| SINV  | (+) ssRNA | Togaviridae     | Vero      | >2 logs (0.3 μM) | >3 logs (0.3 μM) |
| SFV   | (+) ssRNA | Togaviridae     | Vero      | (0.3 μM) \(a\) | (0.3 μM) \(a\) |
| Echo6 | (+) ssRNA | Picornaviridae  | A549      | >1 log (1 μM)  | ND          |
| HSV-1 | dsDNA   | Herpesviridae   | RPE       | ND        | ND          |
| VACV  | dsDNA   | Poxviridae      | RPE       | ND        | ND          |

\(a\), the compound did not affect virus production and survival of infected cells at indicated concentrations.

\(b\), ND, not determined because the compound did not protect cells from IAV-mediated death (see Fig. 7).
the compounds. We found that obatoclax and SaliPhe efficiently (>2 logs reduction in virus titers) attenuated infections of BUNV and SINV, whereas gemcitabine suppressed SINV and HSV-1.

Altogether, these results suggest that obatoclax, SaliPhe, and gemcitabine possess virus-, cell type-, and species-specific antiviral activities, indicating that different viruses could possess differential preferences for cellular targets of obatoclax, SaliPhe, and gemcitabine upon infection.

**Obatoclax, SaliPhe, and Gemcitabine Inhibit Virus Entry**—A time-of-compound-addition experiment in macrophages demonstrated that obatoclax, gemcitabine, and SaliPhe inhibited
early steps of IAV infection (Fig. 3A). An immunofluorescence experiment monitoring the viral NP at 4 hpi revealed that obatoclax and SaliPhe treatment prevented nuclear accumulation of vRNPs which was observed in nontreated and gemcitabine-treated RPE cells (Fig. 3B). Obatoclax, SaliPhe, and gemcitabine treatment affected subsequent vRNA transcription and replication, viral protein synthesis, and infectious viral particle production (Fig. 3, C–E). Thus, these three compounds inhibit entry of IAV into the cells.

Mcl-1 Is a Novel Antiviral Target—Obatoclax is a novel anti-IAV agent, whereas SaliPhe and analogs of gemcitabine have been shown to possess anti-IAV activity (9, 23). Therefore, we investigated the possible mechanism of action of obatoclax.

It was demonstrated that obatoclax preferentially binds Mcl-1 (17); however, the Mcl-1 involvement in IAV infection has not been shown. To prove that Mcl-1 is essential for IAV entry we partially silenced Mcl-1 using Mcl-1-specific siRNA (Fig. 4A), infected these cells with PR8-GFP virus and analyzed virus-mediated GFP expression. Silencing of Mcl-1 substantially reduced IAV-mediated GFP expression and slightly affected the viability of infected cells (Fig. 4B), suggesting that Mcl-1 is involved in IAV infection and apoptosis. Notably, Mcl-1 is up-regulated during the first hours of IAV infection (Fig. 4C) as with other viral infections (24, 25). This result indicates that Mcl-1 could also be involved in host antiviral responses. An immunofluorescence experiment showed that Mcl-1 has a localization pattern similar to that of viral M1 and Mcl-1. DAPI stains the nucleus. Scale bars, 20 μm. E, RPE cells were treated with obatoclax (0.4 μM), stained, and imaged 4 h later. Autofluorescent obatoclax localizes to the perinuclear region of the cells. Scale bars, 10 μm.

Effect of Obatoclax, SaliPhe, and Gemcitabine on IAV-mediated Cellular Antiviral and Proinflammatory Responses—We analyzed the effect of obatoclax, SaliPhe, and gemcitabine on cytokine/chemokine production by IAV-infected and mock-infected cells. We found that all three compounds suppressed WSN-mediated production of proinflammatory IP10, CXCL1, IL6, IL8, CCL2, and CCL5 in RPE cells (supplemental Fig. S3 and Fig. 5). Surprisingly, obatoclax inhibited, whereas SaliPhe and gemcitabine stimulated, production of antiviral IFN-β and
Indeed, inhibition of Mcl-1 with obatoclax suppressed the type I IFN responses in IAV-infected cells. This could be achieved via Mcl-1-mediated regulation of STAT3 signaling pathway which controls type I IFN responses (26–28). Thus, Mcl-1 could be involved in cellular antiviral and apoptosis responses and IAV uptake.

Gemcitabine is an FDA/EMEA-approved anticancer and a novel anti-IAV agent that alters viral RNA transcription and replication. This observation is in line with previously reported findings showing that the analogs of this drug possess anti-IAV activity by targeting ribonucleotide reductase which is essential for de novo pyrimidine biosynthesis (23).

SaliPhe is an investigational anticancer and anti-IAV compound (5, 9, 29). It inhibits vATPase activity, and similarly to ammonium chloride, it prevents the acidification of endosomes and arrests IAV in the endocytic compartments.

In conclusion, we identified obatoclax, gemcitabine, and SaliPhe as potent inhibitors of virus-host interactions, and these results could provide a foundation for clinical development of these host-directed antivirals. These antivirals could overcome the problem of emerging resistance to available virus-directed anti-influenza drugs.

Acknowledgments—We thank Alun Parsons for critical reading of the manuscript; Markus Wolschek for the gift of PR8-GFP IAV strain; Stephen L. White from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, NCI, National Institutes of Health, for compound sets; Ulrich Lauer, from the University Hospital Tuebingen, for the gift of MeV; and Jani Saarela, Caroline Heckman, Maria Anastasina, and Minttu Kaloinen for technical assistance.

REFERENCES
1. Gu, J., Xie, Z., Gao, Z., Liu, J., Korteweg, C., Ye, J., Lau, L. T., Lu, J., Gao, Z., Zhang, B., McNutt, M. A., Lu, M., Anderson, V. M., Gong, E., Yu, A. C., and Lipkin, W. I. (2007) H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 370, 1137–1145
2. Kurtz, J., Manuell, R. J., and Banks, J. (1996) Avian influenza virus isolated from a woman with conjunctivitis. Lancet 348, 901–902
3. Weinheimer, V. K., Becher, A., Tonnies, M., Holland, G., Knepper, J., Bauer, T. T., Schneider, P., Neudecker, J., Ruckert, J. C., Szymanski, K., Temmesfeld-Wollbrueck, B., Gruber, A. D., Bannert, N., Suttorp, N., Hippenstiel, S., Wolff, T., and Hocke, A. C. (2012) J. Infect. Dis., in press
4. Muller, K. H., Kakkoila, L., Nagaraj, A. S., Chelskov, A. V., Anastasina, M., and Kainov, D. E. (2012) Emerging cellular targets for influenza antiviral agents. Trends Pharm. Sci. 33, 89–99
5. Lefebvre, S., Jaunbergs, J., Roth, M. G., Ferguson, D. A., and De Brabander, J. K. (2008) Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigran synthesis of the potent salicylhydrazide analog saliphenolphalalimide. Bioorg. Med. Chem. Lett. 18, 5879–5883
6. Lietzén, N., Ohman, T., Rintahaka, I., Jalkunen, I., Aittokallio, T., Mattikainen, S., and Nyman, T. A. (2011) Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages. PLoS Pathog. 7, e1001340
7. Guse, K., Sloniecka, M., Diaconu, I., Ottolino-Perry, K., Tang, N., Ng, C., Le Boeuf, F., Bell, J. C., McCarty, J. A., Ristimäki, A., Pesonen, S., Cerullo, V., and Hemminki, A. (2010) Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J. Virol. 84, 856–866
8. Heikkilä, O., Susi, P., Stanway, G., and Hyytiä, T. (2009) Integrin αvβ6 is high-affinity receptor for coxsackievirus A9. J. Gen. Virol. 90, 197–204
9. Müller, K. H., Kainov, D. E., El Bakouri, K., Saielens, X., De Brabander, J. K., Kittel, C., Samm, E., and Muller, C. P. (2011) The proton transloca-
Potent Influenza Antivirals

...